×

Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA® (adalimumab) Biosimilar, at EULAR 2016

CAMBRIDGE, Mass., June 08, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that key data from a pharmacokinetic/safety study of M923, the Company’s lead biosimilar candidate developed in collaboration with Baxalta, now part of Shire plc, will be presented at the European League Against Rheumatism Annual Congress (EULAR) 2016 Annual Meeting in London.

The poster, which summarizes topline results for a randomized, double-blind, three-arm, parallel group, single-dose study that was designed jointly by Momenta, Baxalta, and Quintiles, Inc., met its primary endpoint late last year. Pharmacokinetic, safety, and immunogenicity data for M923 compared with U.S.- and EU-sourced HUMIRA reference products will be presented.

Poster Presentation Details

Poster #FRI0182: A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (a Proposed Biosimilar to Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects
Presentation Date/Time: Friday, June 10, 2016; 11:45 a.m. local time
Presenter: Jan Hillson, MD; Vice President, Clinical Research, Momenta Pharmaceuticals

About M923, a proposed biosimilar of HUMIRA® (adalimumab)

M923 is developed in collaboration by Baxalta Incorporated, now part of Shire plc, and Momenta Pharmaceuticals. HUMIRA, the largest selling therapeutic on the market today, is a significant intervention for patients with autoimmune/inflammatory diseases. Adalimumab is used to treat many such conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Investor Relations: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 IR@momentapharma.com Media Relations: Karen Sharma MacDougall Biomedical Communications 1-781-235-3060 Momenta@macbiocom.com

Source:Momenta Pharmaceuticals, Inc.